Skip to content
Open access

Linking early and late endpoints in adjuvant immunotherapy trials: an evaluation of multiple clinical outcomes

Aug 2026 · The Oncologist · Vol 31 · 0 citations · 52 references
Medicine

TL;DR

Strict-primary analyses did not demonstrate a consistent or precise early-endpoint–OS relationship, andarse later windows and uncertainty in both treatment-effect estimates preclude surrogate validation.

Abstract

Abstract Background Overall survival (OS) in adjuvant and perioperative immunotherapy trials requires prolonged follow-up. We examined whether treatment effects on disease-free survival (DFS) and recurrence-free survival (RFS) were associated with OS at matched 2-, 3-, and 5-year windows. Methods The main analysis included 23 strict-primary randomized trials. DFS and RFS were modeled separately across 6 paired time windows using 2 co-primary trial-level approaches: a conventional OS-variance-weighted regression and a conditional errors-in-variables model accounting for uncertainty in both log-HRs. Because within-trial correlations were unavailable, ρ was varied from 0 to 0.75. Eligibility-sensitivity studies were supplementary; broad-taxonomy evidence was excluded. EFS was descriptive, PFS and PFS2 were analyzed separately, and QoL regression required at least 5 verified contrasts. Results Nineteen trials contributed 2-year same-window pairs (12 DFS; 7 RFS), 8 contributed 3-year pairs, and 5 contributed 5-year pairs. For 2-year early endpoints vs 2-year OS, weighted slopes were 0.014 (95% CI, −0.286 to 0.314) for DFS and 0.630 (95% CI, −1.243 to 2.502) for RFS. Eight of 9 fitted weighted-regression intervals included zero; the only nominally positive result involved 4 RFS trials. In errors-in-variables analyses, slopes for the largest DFS and RFS comparisons ranged from 0.011 to 0.264 and from 0.758 to 0.885, respectively, and all profile CIs included zero. Six strict-primary QoL contrasts were verified, but no window reached n = 5. Conclusion Strict-primary analyses did not demonstrate a consistent or precise early-endpoint–OS relationship. Sparse later windows and uncertainty in both treatment-effect estimates preclude surrogate validation.

Read PDF

Similar papers

Open access Oct 2026

Surrogacy between event-free survival and overall survival in perioperative immunotherapy trials.

623 Background: EFS/DFS are commonly used endpoints in perioperative immune checkpoint inhibitor (ICI) trials, but their reliability as surrogates for overall survival (OS) remains uncertain. For surrogacy to be established there should be strong and consistent correlation between the surrogate and definitive e...

Haritha Gandicheruvu, A. Mittal, Manpreet Saini et al. · 0 citations
Review Open access Sep 2026

Immune checkpoint inhibitors across neoadjuvant, perioperative, and adjuvant settings for resectable non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials

Background Randomized evidence for immune checkpoint inhibition in resectable non-small-cell lung cancer has progressed from pathological response to mature survival outcomes. We examined exploratory directional alignment across endpoints and quantified clinical yield, treatment burden, and the extent of perioperative...

J. Dai, Meng-Ni Liu, Hu Li et al. · 0 citations
Sep 2026

Treatment Effect Discrepancy Between PFS and OS in Antibody-Drug Conjugate Trials for Metastatic Breast Cancer: A Meta-Epidemiologic Analysis.

OBJECTIVE The validity of progression-free survival (PFS) as a surrogate for overall survival (OS) in the antibody-drug conjugate (ADCs) era remains uncertain. We evaluated the association between treatment effects on PFS and OS in randomized trials of ADCs for metastatic breast cancer (mBC) and explored the surrogate...

L. F. Costa de Almeida, A. Cappellaro, M. Noronha et al. · 1 citation
Review Open access Oct 2026

Clinical Endpoints in Trials of Metastasis-Directed Therapy in Oligometastatic Cancer: A Systematic Review and Surrogacy Analysis.

BACKGROUND The oligometastatic state is characterized by limited metastatic burden for which metastasis-directed therapy (MDT) may provide durable control. Endpoint selection in MDT trials is poorly standardized and may not reflect long-term benefit or patient priorities. We systematically reviewed clinical endpoints i...

David C. Chen, E. Khosh Kish, Seung-Min Lee et al. · 0 citations
Review Oct 2026

Do progression-free survival benefits justify increased toxicity and treatment burden? A meta-regression analysis of phase III immune checkpoint inhibitor trials from a value-based oncology perspective.

PFS showed a limited and treatment-type-dependent association with OS, and PFS gains frequently accompanied increased toxicity.

Zhen-Yang Long, Tian-Tian You, Yu-Qi Zhao · 0 citations
Review Open access Sep 2026

Efficacy and safety of immunotherapy in pediatric malignant brain tumors: a systematic review and exploratory meta-analysis

Background Immunotherapy for pediatric brain tumors has expanded rapidly, yet its effects on survival and neurologic safety remain unclear. A systematic review and meta-analysis was conducted to quantify efficacy and toxicity across immunotherapy modalities. Methods Following PRISMA 2020 guidelines, prospective pediatr...

Tomasz Tykocki · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.